Horizon Discovery Group plc Director/PDMR Shareholding (0885T)

TIDMHZD

RNS Number : 0885T

Horizon Discovery Group plc

15 March 2019

Horizon Discovery Group plc

15 March 2019

Horizon Discovery Group plc

Director/PDMR Shareholding

Cambridge, UK, 15 March 2019: Horizon Discovery Group plc (LSE: HZD) ("Horizon", "the Group" or "the Company"), a global leader in gene editing and gene modulation technologies, announces that 70,730 options were granted today over the Company's ordinary shares of 1 pence each ("Ordinary Shares") to Terry Pizzie, CEO, in accordance with the Company's Long Term Incentive Plan. The options have an exercise price of 1 pence per share and will vest equally on each of the second and third anniversaries of the grant date.

The options granted are equivalent to 0.047% of the Company's existing issued share capital.

ENDS

For further information from Horizon Discovery Group plc, please contact:

Horizon Discovery Group plc

Terry Pizzie, Chief Executive Officer

Jayesh Pankhania, Chief Financial Officer

Tel: [phone]

Numis Securities Limited (Broker and NOMAD)

Michael Meade / Freddie Barnfield / Duncan Monteith

Tel: [phone]

Consilium Strategic Communications (Financial Media and Investor Relations)

Mary-Jane Elliott / Matthew Neal / Melissa Gardiner

Tel: [phone]

Email: [e-mail]

About Horizon Discovery Group plc www.horizondiscovery.com

Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world leader in gene editing and gene modulation technologies. Horizon designs and engineers cells using its translational genomics platform, a highly precise and flexible suite of DNA editing tools (rAAV, ZFN, CRISPR and Transposon) and, following the acquisition of Dharmacon, Inc., its functional genomics platform comprising gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for research and clinical applications that advance human health. Horizon's platforms and capabilities enable researchers to alter almost any gene or modulate its function in human or mammalian cell-lines.

Horizon offers an extensive range of catalogue products and related research services to support a greater understanding of the function of genes across all species and the genetic drivers of human disease and the development of personalised molecular, cell and gene therapies. These have been adopted by over 10,000 academic, drug discovery, drug manufacturing and clinical diagnostics customers around the globe, as well as in the Company's own R&D pipeline.

Horizon is headquartered in Cambridge, UK, and is listed on the London Stock Exchange's AIM market under the ticker "HZD".

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                    Terry Pizzie 
      --------------------------------------  ----------------------------------- 
 2     Reason for the notification 
      --------------------------------------------------------------------------- 
 a)    Position/status                         Chief Executive Officer - PDMR 
      --------------------------------------  ----------------------------------- 
 b)    Initial notification /Amendment         Initial Notification 
      --------------------------------------  ----------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------- 
 a)    Name                                    Horizon Discovery Group plc 
      --------------------------------------  ----------------------------------- 
 b)    Legal Entity Identifier                 213800L812B9NI5M3G89 
      --------------------------------------  ----------------------------------- 
 4     Details of the transaction(s): section to be repeated for 
        (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------- 
 a)    Description of the financial            Options over ordinary shares 
        instrument, type of instrument          of 1.0 pence each 
        Identification code 
                                                GB00BK8FL363 
      --------------------------------------  ----------------------------------- 
 b)    Nature of the transaction               Grant of Options 
      --------------------------------------  ----------------------------------- 
 c)    Currency                                GBP 
      --------------------------------------  ----------------------------------- 
 d)    Price(s) and volume(s)                   Exercise Price     No. of shares 
      --------------------------------------  ------------------  --------------- 
                              GBP0.01                                  70,730 
  --------------------------------------------------------------  --------------- 
 
 e)    Aggregated information 
        - Aggregated volume 
        - Price                                  n/a 
        - Aggregated total 
      --------------------------------------  ----------------------------------- 
 f)    Date of the transaction                 15 March 2019 
      --------------------------------------  ----------------------------------- 
 g)    Place of the transaction                Off market 
      --------------------------------------  ----------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHDELFFKXFZBBL

(END) Dow Jones Newswires

March 15, 2019 13:44 ET (17:44 GMT)